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Abstract
Background: Human T-cell leukemia virus type-1 (HTLV-1) carriers co-infected with and hepatitis C virus (HCV)
have been known to be at higher risk of their related diseases than mono-infected individuals. The recent studies
clarified that IL-28B polymorphism rs8099917 is associated with not only the HCV therapeutic response by IFN, but
also innate immunity and antiviral activity. The aim of our research was to clarify study whether IL-28B gene
polymorphism (rs8099917) is associated with HTLV-1/HCV co-infection.
Results: The genotyping and viral-serological analysis for 340 individuals showed that IL-28B genotype distribution
of rs8099917 SNP did not differ significantly by respective viral infection status. However, the IL-28B mRNA
expression level was 3.8 fold higher in HTLV-1 mono-infection than HTLV-1/HCV co-infection. The high expression
level was associated with TT (OR, 6.25), whiles the low expression was associated with co-infection of the two
viruses (OR, 9.5). However, there was no association between down-regulation and ATL development (OR, 0.8).
Conclusion: HTLV-1 mono-infection up-regulates the expression of IL-28B transcripts in genotype-dependent
manner, whiles HTLV-1/HCV co-infection down-regulates regardless of ATL development.
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Introduction
A retrovirus, human T-cell leukemia virus type-1
(HTLV-1), and a positive-strand RNA virus, hepatitis C
virus (HCV), are completely different in terms of virolo-
gic characteristics. Nevertheless, they play a similar role
in the pathogenesis of viral-induced malignant neo-
plasms, such as adult T-cell leukemia (ATL) in HTLV-
1- infected individuals, and hepatocellular carcinoma
(HCC) and B-cell lymphoma in HCV- infected indivi-
duals, during long-term chronic infections.
Furthermore, it is known that co-infection with HCV
and HTLV-1 is frequently observed in an area endemic
for HTLV-1. HCV/HTLV-1 co-infected individuals have
been reported to be at higher risk for developing HCC
than those infected with HCV alone [1-3]. Although the
pathologic mechanism of the co-infection remains to be
elucidated, it is thought that the impaired immunity due
to HTLV-1 infection may contribute to HCV infection
and HCV-related disorders, which is suggested by pre-
vious reports. Kohno et al. reported that the severe
immunodeficiency and anergic state in patients with
ATL may be associated with a functional property of
leukemic cells originating from regulatory T-cells
expressing CD4, CD25, CCR4, GITR and Foxp3 [4].
Kishihara et al. also reported that impairment of the
immune response by HTLV-1 could explain the reduced
effectiveness of interferon (IFN) treatment in patients
co-infected with HTLV-1 and HCV [5].
* Correspondence: kamihira@nagasaki-u.ac.jp
1Department of Laboratory Medicine, Nagasaki University Graduate School of
Biomedical Sciences, Nagasaki, 852-8501, Japan
Full list of author information is available at the end of the article
Kamihira et al. Virology Journal 2012, 9:40
http://www.virologyj.com/content/9/1/40
© 2011 Kamihira et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Recently, genome-wide association studies of patients
with HCV have made great advances in viral clearance
associated with IL-28B single nucleotide polymorphisms
(SNP) [6,7]. IL-28B is a type III Lambda interferon
(IFN-l) and a cytokine similar to IL-10 with IFN-like
activities [8]. This new IFN-l family includes IFN-l1
(IL-29), IFN-l2 (IL-28A) and IFN-l3 (IL-28B) [9].
Although the IFN-l genomic structure resembles that of
the IL-10 family [10], the amino acid and functional
level of IFN-ls are more closely related to type I IFNs
than IL-10. The IFN-ls are induced by stimulation with
several single-strand RNAs (ssRNA) and several kinds of
viruses. The IL-28B SNPs, such as rs8099917,
rs12979860, and 12980275, have been reported to be
associated with spontaneous clearance [10], innate HCV
immunity [9], HCV-related disease chronicity, and ther-
apeutic response to pegIFN-a and ribavirin (RBV) [6,7].
From these observations, we hypothesized that IFN-l3
encoded from the IL-28B gene would be associated with
HTLV-1 infection. The aim of the present study was to
examine the mutual association between IL-28B poly-
morphism (rs8099917 SNP) and mono-infected-HTLV-1
and co-infected HTLV-1 with HCV subjects.
Materials and methods
Clinical subjects
All subjects were of Japanese origin living in Nagasaki
City, an endemic area for HTLV-1 in Japan. For geno-
mic specimens, 340 blood samples were randomly col-
lected from patients who visited a liver clinic and liver
transplantation center from April 2009 to March 2011
from the departments of Hepatology and a Hematology
Clinic. One hundred and twenty-four of the 340 samples
were also available for total RNA tests. Accordingly,
most patients had either chronic liver disease (CLD) or
adult T-cell leukemia (ATL). This study was done under
informed consent after the approval of the Nagasaki
University hospital IRB (IRB Approval No.10050). Since
the samples used here were un-linked materials, patient
information was restricted.
Cell lines
Eight HTLV-1-infected T-cell lines, Hut 102, MT-1,
M T - 2 ,S T 1 ,K K 1 ,K O B ,O M T ,a n dL M Y - 1 ,w e r eu s e d
for IL-28B mRNA quantification. The first three were
purchased and latter five were established in our labora-
tory [11].
Serological and genetic tests for HCV and HTLV-1
HCV and HTLV-1 infections were mainly serologically
detected using commercially available kits, CLEIA-anti-
HTLV-1, Lumipulse-II Ortho HCV (Fujirebio-INC,
Tokyo, Japan). The confirming examination was geneti-
cally performed by the Cobas TaqMan HCV test
( T a q M a nH C V ;R o c h eT o k y oI N C ,T o k y o ,J a p a n )f o r
HCV and in-house HTLV-1 proviral real-time RT quan-
tifiable PCR [12]. Genomic DNA and total RNA were
extracted from peripheral blood mononuclear cells
(PBMC) using commercially available QuickGene DNA
Whole blood kits (FUJIFILM Corp., Tokyo, Japan) and
PureLink RNA Micro Kits (Invitrogen Corp., Carlsbad,
Ca, USA). The extraction protocol was performed
according to the manufacturer’s instructions.
Genotyping for SNPs
SNP genotyping was performed using multiplex PCR
amplification and Pyrosequencing technology. To
amplify target regions, newly designed biotinylated-pri-
mers were employed: sense and anti-sense for
rs8099917, 5’-TCCTCCTTTTGTTTTCCTTTCTG-3’
and 5’-AAAAAGCCAGCTACCAAACTGT-3’.T h e n ,
the amplicon was sequenced according to the manufac-
turer’s instructions based on Pyrosequence technology
(Qiagen, Hilden, Germany). Biotin-labeled amplicons
from the 1st PCR were captured by binding to streptavi-
din-coated Sepharose beads, and DNA was denatured to
produce an ssDNA template for the Pyrosequencing
assay. The ssDNA was released and combined with the
sequencing primer, which was extended during the Pyr-
osequencing reaction to provide the sequence of the
template DNA. Pyrosequencing data were produced in
the form of Pyrograms, and genotypes were assigned by
the peak pattern presented in the Pyrogram.
Real-time reverse transcription (RT) quantifiable PCR for
IL-28B mRNA
mRNA for IL-28B transcribed into cDNA by a
GoScript
™ RT System (Promega, Madison, WI, USA)
was quantified by a LightCycler System (Rosche, Man-
nheim, Germany) using newly designed sense and anti-
sense primers, 5’-AAGGACTGCAAGTGCCGCT-3’ and
5’-GCTGGTCCAAGACATCCC-3’ (AY129149). A stan-
dard curve was generated using a tenfold dilution
method with a reference material derived from pTAC-
1.2735 inserted with 166 base fragments including the
target. The amplicon was assayed by the Cyber green
method. The raw data were normalized by abl mRNA
density and evaluated as the relative value for abl gene
expression calculated by IL-28B data/abl data × 10
4,
modified from our previous mRNA real time RT qPCR
method [12].
Statistical analysis
The minor-allele frequency (MiAF) was set as the less
frequent allele in a population for SNPs analyzed. Viral
infectious status was divided into 4 groups of HTLV-1
mono-infection, HCV mono-infection, HTLV-1/HCV-
co-infection, and non-infection (double negative; DN).
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among groups were compared using the Chi-square or
Fisher exact test. The level of mRNA expression was
compared using the Mann Whitney U test. Correlation
analysis was performed by the Nonparametric Spear-
man’s rank correlation method. The relationship
between a factor and an outcome was estimated the
magnitude of the association by the odds ratio with 95%
confidence intervals (95%CI). Statistical analysis was per-
formed using SAS 9.1. The statistical significance level
was set at 0.05.
Results
IL-28B genotypes and the sero-status
Three hundred and forty samples were genotyped on IL-
28B rs8099917 SNP and were serologically examined for
viral infection of HTLV-1 and HCV. As summarized in
Table 1. They consisted of 263 (77.4%) major TT homo-
zygotes, 171 (20.9%) minor TG heterozygotes, and 6
(1.8%) minor GG homozygotes. The virus tests revealed
that 59 were negative for both HTLV-1 and HCV, 73
were positive for HTLV-1 alone, 179 were positive for
HCV alone and 29 were positive for both viruses. The
genotypic distributions, as well as minor allele frequency
(MAF) of the IL-28B gene, did not significantly differ
among each viral infection status as a control of no-
infection.
Since the HTLV-1 mono-infection group consisted of
47 ATL patients and 26 HTLV-1 carriers, we stratified
the two groups of ATL patients and carriers and the
minor allele frequencies of the two groups were com-
pared; the difference between that of ATL and carriers
was not statistically significant (p = 0.21). The preva-
lence of TT was not different statistically either (p =
.495).
Next, the expression levels of IL-28B were quantified
using 124 samples randomly collected during this study
period.
IL-28B mRNA expression level and HCV/HTLV-1 co-
infection
The expression levels of IL-28B mRNA were generally
low in most cases with a median value of 5.2 in no-
infection, 10.6 in HTLV-1 mono-infection, 3.9 in HCV
mono-infection, and 2.8 in HTLV-1/HCV co-infection
(Figure 1a). Notably, a small number of measurement
values shown as open circles was high, and they were
distributed only within the HTLV-1 mono-infected and
HCV mono-infected groups. Moreover, all of those who
had high values were exclusively TT homozygous, as
shown in Figure 1b (samples marked by
A-E) were the
same in Figure 1(a) and Figure 1(b)). Surprisingly, the
median value was the highest in HTLV-1 mono-infec-
tion and the lowest in the co-infection group (10.6 ver-
sus 2.8; p = 0.013). Therefore, to clarify whether ATL
cells directly affect the expression of IL-28B mRNA, we
compared the mRNA expression levels in mainly
HTLV-1 carriers, ATL patients with ATL cells, and
ATL cell lines. As shown in Figure 2, the median values
were significantly higher in mono HTLV-1 carriers with
TT (17.9 vs 5.6, P < 0.05) and ATL patients with TT
having ATL cells than those of non-infected individuals
(13.4 vs 5.6, p <0 . 0 5 ) .N oh i g he x p r e s s i o nl e v e lw a s
observed in two ATL or 16 carriers with HTLV-1/HCV
co-infection. Surprisingly, these data were lower rather
those from TG/GG. On the other hand, IL-28B mRNA
expression in 8 HTLV-1-infected T-cell lines was unde-
tectable in all but one (Hut 102). The genotype was TT
in all cell lines.
In addition, there was no correlation between the IL-
28B mRNA levels and HCV-RNA levels (non-parametric
Spearman’s rank correlation, R
2 = 0.0543, Figure 3).
Assessment by odds ratio analysis for an outcome if a
risk factor is present
As shown in Figure 2, HTLV-1 was revealed to have an
association similar to HCV and IL-28B mRNA. How-
ever, the up-regulated-action of HTLV-1 was nullified if
the virus was co-infected with HCV. The prevalence of
a major TT and minor TG/GG was similar among indi-
viduals infected with either HTLV-1 or HCV, as well as
the allele frequency, indicating that there is no specific
correlation between IL-28B and HTLV-1. Thus, to
approach a causative clue, assessment by odds ratio
(OR) analysis was performed (Table 2). Only the high
mRNA level besides 3 states of HTLV-1 mono-infection,
Table 1 IL-28B genetic distribution and allele frequency
in stratification based on the combination of HTLV-1 and
HCV infection
Genotype r(rs8099917) Allele fequency
No TT TG GG T G
All cases 340 263
(77.4%)
71
(20.9%)
6
(1.8%)
0.86 0.14
1) non-Infection 59 45(76.3) 10
(16.9)
4(6.8) 0.84 0.15
2) HTLV-1 mono 73 55(75.3) 17
(23.3)
1(1.9) 0.87 0.13 P =
0.90
ATL patients
carriers
47 37(78.7) 10
(21.3)
0(0.0) 0.89 0.11 P =
0.11
26 18(69.2) 7(26.9) 1(3.8) 0.82 0.18 P =
0.46
3) HCV-mmono 179 141
(78.7)
37
(20.7)
1(1.0) 0.89 0.11 P =
0.68
4) co-infection 29 22(75.9) 7(24.1) 0(0.0) 0.88 0.14 P =
0.9
There was no significant difference in the genetic distribution and allele
frequency among respective infectious states
P values were compared with non infection
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Page 3 of 7co-infection with HCV and ATL was associated with TT
genotype (OR = 6.25). On the other hand, down-regula-
tion of the mRNA density was defined as HTLV-1/HCV
co-infection (OR = 9.5 p = 0.004), but low expression
was not associated with ATL development (OR = 0.8, p
= 0.81).
Discussion
Although co-infection with HTLV-1 and HCV has been
shown to result in higher rates of cirrhosis and
increased death from liver diseases [1,2], the caustic
mechanism by which the co-infection affects HCV
pathogenesis remains to be elucidated. Some clue to the
mechanism may be found by studying the relation
between IL-28B genotypes and co-infection, because IL-
28B encoding IFN-ls are categorized as type 3 IFNs and
are potent endogenous anti-viral cytokines. They signal
via JAK/STAT intracellular pathways and up-regulated
transcription of IFN-stimulated genes (ISGs) that are
required to control viral infection [13]. Here, we investi-
gated whether IL-28B polymorphism rs8099917 is asso-
ciated with co-infection status.
The present study is the first to reveal that the IL-28B
genotype is not associated with stratification based on
the combination of HTLV-1 and HCV infection; no
infection for both (double negative; DN), HTLV-1
mono-infection, HCV mono-infection and HTLV-1/
HCV co-infection. Similarly, the frequency of the major
TT homozygotes was not associated among ATL
patients and HTLV-1 carriers (Table 2). These two
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Figure 1 Relative individual IL-28B mRNA levels in peripheral blood mononuclear cells among viral infectious groups (a) and among
the TT and TG/GG genotypes (b). The median values were significantly different between * vs ** and *** vs **. Open circles; those with high
IL28BmRNA with TT homozygotes.
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2) = 0.0543.
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Page 5 of 7findings suggest that the SNP rs8099917 is not asso-
ciated with susceptibility to HTLV-1 infection or the
development of ATL. On the other hand, all of ATL
cell- or HTLV-1-infected T-cell- lines examined were
exclusively TT homozygous, implying that HTLV-1-
infected cells carrying TT homozygotes may immortalize
easily in vitro.
Next, we found a strange phenomenon that the IL-
28B mRNA expression levels in peripheral blood were
lower in samples with HTLV-1/HCV co-infection than
in samples with either HTLV-1 or HCV alone, especially
significantly for HTLV-1 mono-infection. In particular,
samples carrying TT homozygotes were strongly down-
regulated, more than the minor TG hetero- and GG-
homozygotes. Why are the mRNA expression levels dif-
ferent in mono- and dual-infection? Although it is not
known how rs8099917 affects the action of IL-28B, pre-
sumably it alters the immune function to viruses. In
addition to a common anti-viral IFN-stimulating signal
pathway, HTLV-1 may use an alternative anti-viral path-
w a yl i k eH B V[ 1 4 ] ,b e c a u s et h eH T L V - 1p r o v i r u si s
integrated into host genomic DNA and replicates in dis-
tinctive life cycle kinetics. Moreover, ATL originates
from Treg cells, which play a central role in suppressing
immunity [15]. However, this cannot fully explain the
impairment in the HTLV-1 carrier’s immunity because
no ATL cells are present during the carrier period.
Thus, we noted IFN-l(IL-29, IL-28), which was recently
discovered as a type III IFNs with anti-virus ability, anti-
tumor and immune responses [16-18].
From our results, the IL-28B expression level was
higher in HTLV-1 mono-infected individuals including
ATL patients. IFN-lis usually up-regulated through acti-
vation of the NF-kappaB pathway after viral infection.
Actually, the Sendai virus, an influenza A virus, and
others have been demonstrated to activate the NF-kappa
B pathway, resulting in up-regulated IL-28B expression
[19,20]. Accordingly, the highest up-regulation of IFN-
l3 in HTLV-1 mono-infection may be explained by vir-
tue of a viral protein of HTLV-1 having strong NF-kB
activating ability. Moreover, it is instructive that IFN-
lhas a potent function to expand Treg cells [21], which
are mainly infected with HTLV-1, predisposing develop-
ment of ATL. However, there has not yet been evidence
that co-infection with HCV damages Tax action.
Of IL-28B producing cells in the literature, most cells
in the blood are described as having a weak or absent
expression under the steady state conditions. Li et al. [9]
reported that IL-28B mRNA is not always expressed in
virally infected cells. Actually, our findings in HTLV-1-
infected cases also showed that at least the main produ-
cing cells are likely to be cells other than ATL cells
because most cell lines from ATL and some blood sam-
ples containing ATL cells were expressed faintly. At pre-
sent, plasmacytoid dendritic cells are indicated to be the
most potent producers of IFN-ls [19]. On the other
hand, IFN-l3 reportedly has the functions of proliferat-
ing Treg cells which are the origin of ATL cells, sug-
gesting that HTLV-1 is associated with up-regulation via
Treg cells infected with HTLV-1.
In conclusion, we found an unusual phenomenon in
that the expression of IL-28B mRNA was affected by
not only the IL-28B rs8099917 genotype, but also co-
infected HTLV-1 with HCV. This will contribute to a
better understanding the enigmatic impairment of
immunity in the HTLV-1 carrier state, including co-
infection with HTLV-1 and HCV.
Abbreviations
HTLV-1: Human T-cell leukemia virus type -1; HCV: Hepatitis C virus; SNP:
Single nucleotide polymorphism; IFN: Interferon; PBMC: Peripheral blood
Table 2 Assessment by odds ratio analysis for an outcome if a risk factor is present
factor
(A) Outcome dependent independent Odds ratio 95%CI P
1) HTLV-1 mono-infection TT vs TG/GG 1.11 0.62-1.99 0.72
2) Co-infection TT vs TG/GG 0.54 0.04-6.88 1.00
3) High mRNA Expression* TT vs TG/GG 6.25 1.16-33.75 0.04
4) ATL
(B)
TT vs TG/GG 1.50 0.60-3.75 0.39
5) Low mRNA Expression HTLV-1 mono vs DN 0.34 0.06-2.04 0.24
6) Low mRNA Expression HCV mono vs DN 0.29 0.07-2.23 0.15
7)) Low mRNA Expression Co-Inf** vs HTLV-1-mono** 9.5 2.06-43.76 0.004
8) ATL low expression or not 0.8 0.14-4.74 0.81
(A) Upper 4 lines; assessing the risk of 1) HTLV-1 persistent infection, 2) super-imposed HTLV-1 infection with HCV (co-infection), 3) high IL-28B mRNA expression,
and 4) ATL development when the genotype is a risk factor (B) Lower 4 lines; assessing the risk factors described in the outcome, the IL-28B mRNA expression
level in peripheral blood (5, 6, and 7), and ATL development (8). Consequently, similarly to HCV, HTLV-1 is associated with up-regulation of IL-28B mRNA along
with the TT homozygote, and co-infection with HTLV-1 and HCV paradoxically down-regulates the mRNA level
*; IL-28B Expression level, Co-inf = co-infection with HTLV-1 and HCV, mono = mono-infection
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frequency.
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